PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the filing of a provisional patent application in the US for the novel use of ketamine as a potential treatment for Type 2 diabetes and obesity.
The filing of the patent for the indication follows the company evaluating various indications with panaceAI, which is the firms artificial intelligence platform. The platform has reportedly discovered protein bindings and interactions with ketamine that have lead to the compound being a potential treatment for diabetes and obesity. The tech is also reportedly currently evaluating DMT, MDMA, and LSD for future partnering opportunities and clinical development.
An application with the FDA has also been submitted for the use of ketamine as a potential treatment for parkinsons disease under an investigation new drug designation. If accepted, the company intends to expand the phase 2 clinical trial to include these new indications.
“We continue to focus on building our patent and product portfolio of prescription-based psychedelics through our drug repurposing and delivery methods for unmet medical needs. Our strategy is to investigate ketamine in FDA Phase 2 clinical trials for Parkinson’s disease and depression and with panaceAI™, we aim to find new uses of psychedelics, such as ketamine, psilocybin, DMT, MDMA and LSD, and incorporate them into our proprietary microneedle patch delivery system.”
Fabio Chianelli, CEO of PharmaTher
PharmaTher last traded at $0.24 on the CSE.
Sponsored · Selkirk Copper Mines
FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
